Unlike programs focused on illness, Metanoia explores natural psychedelics for personal growth in healthy adults: integrating six disciplines for a 360° understanding of whether and how they affect creativity, cognition, and emotional resilience.
Published Updated Last reviewed 2 October 2026
Multidisciplinary Research
Six integrated disciplines driving a 360° understanding
One question runs through all of them: how do we thrive?
Neuroscience
How psychedelics change brain activity, neuroplasticity, and cognition, and what that means for creativity, focus, and emotional resilience in healthy adults.
Still openOthers are asking nowMetanoia will studyWhyRead the full research focusClose
Still open
Whether anything measurable in the brain still differs months after an experience in a healthy adult, and whether it tracks what the person set out to change.
Others are asking now
A 2026 mega-analysis pooled eleven brain-imaging datasets across five psychedelics and found more communication between large-scale brain networks (Girn et al., Nat Med, 2026).
Metanoia will study
An EEG and physiology laboratory, brain imaging through an established medical partner, and whether a durable plasticity marker exists in living people, given that blood BDNF did not move in a healthy-adult trial.
Why
Neuroscience can tell us whether a claimed change leaves any trace in the body, a precondition for trusting any growth claim.
Studying natural sources, mushrooms, cacti, vines, and bark, as whole chemical systems, not single molecules. Each carries an "entourage" of related compounds that may shape the experience.
Still openOthers are asking nowMetanoia will studyWhyRead the full research focusClose
Still open
Whether the "entourage" of companion compounds in a natural source has any measurable activity of its own, and how much growing conditions change the chemistry a study would actually be testing.
Others are asking now
A check of ChEMBL release 37 (released 1 May 2026), run on 2 October 2026, found no record under the name aeruginascin, one record for baeocystin with no measured value, and nine for norpsilocin, all at the serotonin 2A receptor and drawn from two publications, one from 2020 and one from 2024. The basic pharmacology of these companion compounds is close to unmeasured.
Metanoia will study
Analytical chemistry aligned with AOAC methods, first through a contract laboratory and later in-house, operating only under the required DEA registration.
Why
Closing the basic-pharmacology gap is a precondition for any claim about whole-source effects, and ethnobotany keeps the debt to the Indigenous knowledge this field draws on in view.
Exploring whether genetic factors influence how individuals respond to psychedelics. Understanding that variation is a precondition for any future standard for growth.
Still openOthers are asking nowMetanoia will studyWhyRead the full research focusClose
Still open
Whether any inherited variant ties to the strength of a psychedelic response in people, and why commercial mushroom cultivars that share nearly identical psilocybin genes still differ in strength.
Others are asking now
A 2026 systematic review of 32 trials in healthy volunteers found that the pharmacokinetics of these compounds are still only partly understood (Hampsey et al., 2026).
Metanoia will study
Sequencing and a strain and sample bank on the mushroom side, with any human genetic work only under ethics board review and strict protection of genomic data.
Why
Understanding that variation is a precondition for any future standard for growth, and for knowing who a finding actually applies to.
Developing evidence-based frameworks for preparation, the experience itself, and integration, including the role of set, setting, and meditation.
Still openOthers are asking nowMetanoia will studyWhyRead the full research focusClose
Still open
Which parts of preparation and integration actually change long-term outcomes in healthy adults, and which are habit or ritual, since trials rarely report what happened in the room clearly enough to tell support from psychotherapy.
Others are asking now
The ReSPCT Delphi consensus, built by 89 experts from 17 countries, named 30 non-drug variables that shape a psychedelic experience's setting (Pronovost-Morgan et al., Nat Med, 2025).
Metanoia will study
A research unit that observes and records preparation, support and integration under ethics board approval, aligned with ReSPCT. Metanoia does not provide these services.
Why
Without a shared reporting standard for the surrounding context, no two studies of the same substance can really be compared.
How growing conditions, species, and strain shape a source's real chemistry, the variation that makes reproducible research possible or impossible.
Still openOthers are asking nowMetanoia will studyWhyRead the full research focusClose
Still open
Which growing variables move the chemistry most when the others are held constant, since much of the published variation mixes cultivation with drying, storage and laboratory method.
Others are asking now
Freezing fresh mushrooms before freeze-drying was found to drastically change psilocybin and psilocin levels (Windsor et al., 2026), and a review of 25 studies found extraction method and species both change measured yields (Galdino et al., 2025).
Metanoia will study
Controlled growth rooms, documented drying and storage, a strain bank and quality assurance, prioritizing cultivable sources over threatened or wild ones, operating only under full legal authorization.
Why
Reproducible research needs source material whose variation is measured and recorded, not assumed away, and peyote and iboga carry real ecological and cultural stakes.
How sex and gender shape psychedelic response, one of the least-studied questions in the field.
Still openOthers are asking nowMetanoia will studyWhyRead the full research focusClose
Still open
Whether menstrual cycle phase changes the experience in healthy adults, and whether a sex-disaggregated analysis in a large prospective registry exists at all.
Others are asking now
A pooled analysis of ten studies with 288 participants found no significant association between subjective effects and sex or body weight (Garcia-Romeu et al., 2021).
Metanoia will study
Gender as a lens across every discipline at the planned center: sex-balanced samples, hormonal status recorded where relevant, and results reported by sex as a default.
Why
Women are close to half of recent trial participants, so the gap is in analysis, not presence, and it is closeable now.
Six disciplines, pointed at twelve dimensions of human potential. These are the outcomes our research sets out to understand, and measure. All twelve dimensions now have a published evidence review, with the sources listed on each page.
12 dimensions
Turn the wheel, or tab through it, to open a dimension's research brief.
Reviewed
Creativity
Still open
Whether a single session changes real creative output weeks or months later, in a healthy adult.
Others are asking now
A 2026 meta-analysis of 24 studies and 3,681 healthy participants found microdosing had minimal impact on creativity in blinded trials (Meshkat et al., CNS Drugs, 2026).
Metanoia will study
Whether pairing a session with deliberate creative practice does anything the session alone does not, with tools built to detect change in people already doing well.
Why
Most existing tools were built to detect illness, not improvement above a normal baseline, which may be hiding real effects or hiding nothing.
Why the controlled evidence here is thinner and less encouraging than for other dimensions, and whether that reflects the substance or the tasks used to measure it.
Others are asking now
A 2024 trial gave 80 healthy men a small LSD dose for six weeks with a dedicated problem-solving questionnaire, and nothing moved (Murphy et al., Psychopharmacology, 2024).
Metanoia will study
Whether any controlled or semi-controlled design finds an improvement at all, since every one reviewed so far found no change or a decline.
Why
This is one of the thinnest evidence pages in the field, and stating that plainly matters more than softening it.
Whether the sense of insight people report after an experience holds up as a measurable, lasting change, separate from the intensity of the altered state itself.
Others are asking now
In a population-based sample of over 2,800 American adults, psychological insight, not ego dissolution, predicted more frequent meditation practice afterward when both were tested together.
Metanoia will study
How much of any reported effect comes from the substance itself versus the structured practice often built around it in the same study design.
Why
Self-exploration is the most common reason people give for use outside a lab, so understanding what actually moves is central to the mission.
Why retrospective, subjective ratings of significance hold up so consistently while standardized psychological instruments administered alongside them mostly do not move.
Others are asking now
The largest placebo-controlled microdosing study to date (n=191, citizen-science design) found psychological measures improved as much in the placebo group as the active group.
Metanoia will study
Why three independent, well-designed microdosing studies converged on the same placebo-like pattern, and what a properly blinded macrodose design in healthy adults would need.
Why
A 2,900-person survey found both persisting improvements in mood and, in seven to eleven percent of people, lasting negative effects. Both facts belong in the same sentence, and neither is settled.
Whether a lasting change in social connection after an experience can be separated from the setting it happened in.
Others are asking now
A University of Zurich trial of 122 healthy adults compared psilocybin, MDMA and methylphenidate on prosocial tasks and the Compassion Scale four weeks after dosing. The registry lists it as completed with no results posted (NCT06081179, checked 2 October 2026).
Metanoia will study
Whether a lasting change in connection can be separated from the setting in which the experience happened.
Why
Connection is named in our founding framework as one of the dimensions growth should be measured against.
Whether a measured change in empathy after a psychedelic experience outlasts the hours the substance is active.
Others are asking now
Whether the small, short-lived rise in self-rated emotional empathy seen in the laboratory outlasts the session. The Zurich four-week data are the first likely test.
Metanoia will study
Whether any change in empathy survives a test with real people instead of photographs.
Why
Empathy is one of the twelve dimensions our outcome measure is being built around.
How little the science actually says about faces, landscapes and full scenes, beyond the classic geometric form constants.
Others are asking now
No study we reviewed followed perceptual performance in healthy adults after exposure, so lasting acuity, timing or attention is open in both directions.
Metanoia will study
Whether any lasting change in perceptual performance shows up when healthy adults are tested over time.
Why
Perception is the dimension where the oldest formal science exists, which makes the modern gap more visible, not less.
Whether any lasting change in learning or memory follows an experience in a healthy adult, beyond the acute state.
Others are asking now
The one controlled finding on offline motor learning that the page found, with LSD, has not been replicated and has rival explanations in fatigue, arousal and motivation.
Metanoia will study
Whether the one reported learning gain holds up in a replication with tasks that rule out fatigue and arousal.
Why
It is the closest fit to a hard neuroscience measure among the twelve dimensions, which makes it a natural place to start.
How much of any effect on mindfulness reflects the substance versus deliberate practice built around it in the same study.
Others are asking now
The controlled retreat trials used experienced meditators, who may have less room to improve on the scales, so the question for people new to meditation is open.
Metanoia will study
Whether trait mindfulness changes in healthy adults new to meditation, against both a placebo and a structured training program.
Why
Mindfulness recurs across several other dimensions' evidence bases, so it is likely to inform more than one review at once.
Expanding human consciousness, studied rigorously, shared openly.
The Measurement Problem
Twelve dimensions, and the problem of measuring them
The dimensions above are what our research sets out to understand. There is an awkward problem with that: we have not identified a common instrument that measures them together over time. This is the least glamorous gap in psychedelic science, and we think it is the most important one.
A 2024 systematic review in the Journal of Psychopharmacology examined 93 clinical trials of classic psychedelics and found 17 different rating scales in use across them. Its authors called for the field to develop a core outcome set, a common minimum that every study reports, and recommended that instruments be designed to assess the setting of an experience. We have not identified either in use.
There is a second gap underneath the first. Nearly every validated instrument in the field measures the acute experience: what happened during the hours the substance was active. Very little measures what a person was actually seeking, or whether they found it, a month or a year later. The Oregon cohort of state-regulated psilocybin services records participants' reasons for seeking services at baseline and asks at follow-up whether their goals were met, as items beside symptom and well-being scales, and its published results run to three months (Korthuis et al., JAMA Network Open, 2026). For a field increasingly asked to justify itself with durable outcomes, that is a strange place to be.
The consequence shows up plainly in the research. In what its authors describe as the largest prospective study of naturalistic psilocybin use published to date, participants most often named self-exploration, and most named several reasons at once, mental health and therapy among them. Their outcomes were reported on measures of anxiety, depression, alcohol misuse, cognitive flexibility, emotion regulation, spiritual wellbeing, extraversion, neuroticism, and burnout. The purpose a person recorded and the instrument that measured the outcome came from different frames. That same study found that, of those who completed each follow-up, 11% at two to four weeks and 7% at two to three months reported persisting negative effects, and we have not identified a standard for how such an effect should be defined, timed, or recorded.
So results are hard to pool across studies, benefits are hard to compare, and harms are hard to count properly. Every new dataset arrives in its own dialect.
What we are building
Three pieces, all of them plumbing rather than headline science:
A minimum common data element set, the short list of facts any record of a psychedelic experience should carry to be comparable with any other: substance and whether its identity was verified, preparation form, quantity with units and route, setting and supervision, screening performed, medications, and what followed, at fixed intervals.
An outcome measure referenced to purpose, built on the twelve dimensions above, and anchored to what the person recorded before the experience rather than what they remember afterwards. Purpose recorded in advance is a fixed reference point. Purpose recalled later tends to be revised in light of how things turned out.
A standard case definition for persisting adverse effects, with fixed observation windows, so that the persisting-effects finding above becomes a number that can be checked, compared, and either confirmed or corrected.
All of it will be published openly and free of charge, with no licence fee and no restriction on use, for researchers, state programmes, registries, and clinicians to adopt or adapt. The first piece is out: version 1.1 of the minimum common data element set, 23 elements in six groups with a proposed case definition for persisting adverse effects, is open for public comment until 2 December 2026. The outcome measure is still in development.
Public Comment
What we asked the FDA
On September 22, 2026, Metanoia submitted a written comment to the U.S. Food and Drug Administration in docket FDA-2026-N-7542, its public proceeding on psychedelic drugs. On September 14 we spoke at the agency's public hearing. Metanoia was among the speakers randomly selected from the requests received.
Federal funding is about to reach state psychedelic programs, and we asked the FDA to settle what every record should contain before those databases are built.
From the FDA's webcast: Metanoia's founder gives our two-minute oral remarks at the public hearing on psychedelic drugs, September 14, 2026, as speaker 67. Metanoia was among the speakers randomly selected from the requests received.
Two figures in the spoken remarks came out wrong on the day. The therapy figure should read 47.9 percent, not 78 percent. The executive order is number 14401, not 1441. Both are marked in the transcript below, and our written comment corrects the therapy figure in note 1.
Read the transcript
Good afternoon. My name is Shraga Israel, founder of Metanoia, a California nonprofit public charity that conducts research and public education on natural psychedelics in healthy adults. We have no financial relationships with any company in this field. On topic four, I'm asking for one thing, agreed on common data elements before the databases are built, not after. Executive Order 1441 [Correction: the order is Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, 91 Federal Register 21709.] directs at least $50 million towards state psychedelics programs, including data sharing. Elements agreed now cost almost nothing. Some can never be added later because they had to be recorded before the person took the drug. The reason for use is the clearest case. A survey of real world psilocybin use asked about 1,800 people why they were taking it before they did. 81% replied self exploration. 71% replied mental health. 78% replied therapy. [Correction: the figure for therapy is 47.9 percent, not 78 percent. Source: Nayak et al., Frontiers in Psychiatry, 2023, survey 3, n = 1,802.] The same people, several reasons each. Non-medical records have no indication field. So databases that reads an empty field as non-medical get most of these people wrong. So we recommend two fields. One, was a condition clinically diagnosed. Two, the person's own reason, more than one if needed, with the date they were recorded. Metanoia is drafting these elements and an outcome instrument built around the reason for use and will publish both openly free of charge. My request is simple. Make data that can be compared a design requirement from day one, not a repair job after data exist. Thank you.
A word on what this is not. We are not claiming to be an authority, and a measure is not made legitimate by being announced. It earns its place by being used, tested, and criticised until either it survives or something better replaces it. So we publish drafts rather than verdicts, we invite people to take them apart, and we will say plainly where we got it wrong. Metanoia is well suited to this particular job for one structural reason: we sell nothing to the people our research informs, so no finding is worth more to us than any other.
The Family We Study
Eight substances, one open notebook
Metanoia did not start with mushrooms and move on to the rest. We started with the classic psychedelics as a family, six natural sources and two synthetics studied for a complete picture, and psilocybin is simply the one with the most work behind it so far. Each brief below is our open question for that substance, not a verdict on it.
These eight cards are research briefs: what remains open, what others are studying now, what Metanoia will ask, and why. For what is already established and readable today, see Education, where the same eight substances live as books that keep updating, one link per card below.
Research agenda
Psilocybin mushrooms
Fungus · natural
How much of the whole-mushroom "entourage" idea is real chemistry, and how much is a measurement gap we can close.
Two registered trials give participants whole mushroom material rather than the pure molecule, one in Arizona and one in Brazil, both in clinical populations only (ClinicalTrials.gov NCT07347405, NCT06898606, verified 22 September 2026).
Whether the whole mushroom differs from pure psilocybin at a matched dose, in the same protocol, in a healthy adult.
Metanoia's population, healthy adults with no diagnosis, sits entirely outside both existing whole-mushroom trials.
What DMT does on its own, in someone with no diagnosis, separate from its role inside ayahuasca.
DMT's literature overlaps heavily with ayahuasca's because the body breaks DMT down the same way ayahuasca's vine is designed to block (Metanoia literature scan, 17 August 2026).
How much of what is "known" about DMT actually belongs to DMT alone versus the ayahuasca combination.
Its extremely short duration makes it a different research object from psilocybin or LSD, and almost nothing isolates it in a growth-oriented design.
Which of the field's own consensus context variables actually move the outcome for a healthy person seeking growth, not symptom relief.
A 2025 Delphi consensus of 89 experts across 17 countries, ReSPCT, named 30 non-drug variables that shape a psychedelic experience's setting (Nature Medicine, PMID 40461819).
A screening and safety framework for a non-clinical, healthy-adult population, since MAO-inhibitor interaction protocols so far exist only for clinical settings.
Ayahuasca is the field's clearest case of an "entourage": two plants, neither active alone by mouth.
Whether a conservation-first research design can work at all, given real ecological pressure on wild peyote.
Some of the oldest formal descriptions of psychedelic visual experience, roughly a century old, were built on mescaline, yet almost none of the modern research wave studies it directly.
Whether faster-growing, more readily cultivated columnar cacti (San Pedro and related species) can anchor a responsible research supply chain instead of peyote.
Most of what gets inferred about mescaline is borrowed from psilocybin or LSD research on the same receptor family, and that borrowing is untested.
Whether iboga research in healthy volunteers is possible at all, and what cardiac screening would make it responsible.
A rat study found that ibogaine raised the expression of the genes for both BDNF and GDNF, proteins associated with neural growth (Marton et al., Frontiers in Pharmacology, 2019). In humans, MISTIC was an open-label, uncontrolled study of 30 male veterans with traumatic brain injury, most of whom also met criteria for PTSD at baseline (Cherian et al., Nature Medicine, 2024). It reported improvements in disability, PTSD, depression and anxiety, did not measure growth factors, and was not done in healthy adults. Its authors call for controlled trials.
A cardiac safety screening threshold built for a healthy, non-clinical population, since existing safety literature comes almost entirely from clinical or harm-reduction contexts.
Ibogaine's documented QT-prolongation risk is real, and demand for iboga has real consequences for Bwiti communities and Gabon's ecosystems.
Whether whole-source research makes sense at all here, when the natural toad-derived source carries a cardiotoxicity risk the synthetic isolate doesn't.
Most published accounts of its brief, intense effects come from harm-reduction or naturalistic-use reports rather than controlled research, and essentially none focus on healthy adults.
What a healthy-adult, growth-oriented research line looks like for one of the shortest, most intense experiences in the family.
On safety grounds the case for studying the synthetic rather than the natural source may be the strongest exception in Metanoia's whole research family.
What a healthy-population research line built on LSD's unusually clean pharmacological characterization would take.
A randomized, placebo-controlled crossover trial gave healthy adults a single dose of LSD. Blood BDNF did not change at the group level even though a measurable next-day behavioral effect did appear (Calder et al., Neuropsychopharmacology, 2026).
Outcome measures beyond peripheral BDNF alone, building on that trial's healthy-adult design.
It is one of this family's only randomized trials done entirely in healthy adults, and it complicates a popular biomarker rather than confirming it.
Classic synthetic · empathogen, covered for a complete picture
What it means to study a substance that doesn't share this family's core receptor mechanism inside a program built around growth, not symptom relief.
The clinical MDMA literature is comparatively large, but built almost entirely around treating a diagnosed condition rather than a healthy population.
Whether or how any of that clinical evidence base translates to healthy adults seeking growth rather than symptom relief.
MDMA works mainly by releasing the brain's own serotonin, an entactogen mechanism, so it may need different outcome measures than the rest of the family.
Four initiatives that turn scattered global knowledge into something people can actually use.
In development
Worldwide Research Database
A continuously updated, science-based library of psychedelic research results: drawn only from trusted, verified sources, and searchable by anyone.
Read more
Ongoing Project
Worldwide Research Database
The science of psychedelics is scattered, across journals, languages, preprints, and paywalls, and most of it never reaches the people who could use it. We are building a single, continuously updated library that gathers verified research results into one place, searchable by anyone, free of charge.
The discipline is strict: every entry is drawn only from trusted, verified sources, with the link and the claim checked to match. Nothing fabricated, nothing exaggerated. Where the evidence is strong we say so, where it is thin or contested, we say that too, because an honest map of what we don't yet know is as valuable as a map of what we do.
This is core to Metanoia's mission: turning complex, fragmented research into knowledge people can actually understand and act on.
In development
Safe-Use Research Digest
A plain-language, dated summary of what current research says about risks, interactions, and contraindications.
Read more
Ongoing Project
Safe-Use Research Digest
Reliable, non-judgmental information about the safe and responsible use of psychedelics is scattered and often drowned out by hype or fear. We are building a written digest that summarizes, in plain language, what current verified research says about interactions, contraindications, and set and setting, with every claim sourced and dated.
It is designed around harm reduction and honesty, not promotion. It will flag real risks clearly: the danger of combining psychedelics with certain antidepressants or MAO-inhibitors, the contraindication for those with a personal or family history of psychosis.
A firm boundary: this is education. It is not a supply service, it does not give personal answers about anyone's use, and it is not a substitute for medical advice.
Open for reports
Field Reports
An anonymous channel for accounts of experiences, and of retreats, centers and practitioners, outside supervised programs, kept as knowledge that would otherwise go unrecorded.
Read more
Ongoing Project
Field Reports
Much of the use of psychedelics for personal growth happens outside any supervised program: at home, at retreats and centers, and with guides and practitioners who work without oversight. What happens there is rarely recorded anywhere a researcher could find it. We run an anonymous channel to collect those accounts as knowledge, on the same data element set we use for every other kind of record.
A report is not a substitute for controlled science, and we never treat it as one. We take no position on the legal status of any setting a report describes, we will publish only combined counts, and the form asks for no identity, no exact dates and nothing about how a substance was grown, made or obtained.
The channel is open. Its privacy terms and publication policy are on the form page.
A common data element set and an outcome measure anchored to purpose, so that results from different studies, programmes, and registries can finally be compared.
Read more
Ongoing Project
Measurement & Data Standards
A 2024 review of 93 clinical trials found 17 different rating scales in use, and its authors called for a core outcome set. We have not identified one in use. Almost every validated instrument in the field measures the acute experience rather than the durable outcome, and we have not identified one designed around what a person was actually seeking. The result is that studies are hard to pool, benefits are hard to compare, and harms are hard to count properly.
We are drafting three pieces of plumbing: a minimum common data element set for any record of a psychedelic experience. An outcome measure built on our twelve dimensions and anchored to the purpose a person records before the experience rather than recalls after it, and a standard case definition, with fixed observation windows, for persisting adverse effects.
All of it will be published openly and free, with no licence fee and no restriction on use. We submitted this work to the U.S. Food and Drug Administration as a written comment on September 22, 2026.
We are not claiming to be an authority. A measure earns its place by being used and criticised, not announced, so we publish drafts, invite people to take them apart, and say where we got it wrong.
One receptor behind most of these substances, and the exceptions
Mesoamerican mushroom traditions, the ayahuasqueros of the Amazon, the peyote traditions of North America and, much later, a Swiss chemist making a new molecule all reached the same receptor from different directions, without knowing it. Not every substance here fits that picture, and the diagram shows where it does not.
PsilocybinDMTAyahuascaMescalineIboga5-MeO-DMTLSDMDMA, a different mechanism, shown separately
Psilocybin, DMT, ayahuasca, mescaline and LSD are, chemically, a match or a near-match for serotonin at one receptor, 5-HT2A, on cells across the brain. Block that receptor and the classic psychedelic effect does not happen. That is the field's actual consensus, not a metaphor about interconnection: an international body of pharmacology, going back decades, agrees that classic psychedelics are agonists or partial agonists at 5-HT2A. Traditions that never had contact with one another built rituals around plants and fungi that, it turns out, share this one action.
Two substances on the ring fit only in part, and the dashed lines mark them. 5-MeO-DMT binds 5-HT2A too, but binds a related receptor, 5-HT1A, far more tightly. Ibogaine, the main alkaloid of iboga, binds with moderate to weak strength to many targets, among them the NMDA receptor, opioid and sigma receptors and the serotonin and dopamine transporters. The details and sources are on the 5-MeO-DMT and iboga pages.
MDMA sits outside the ring on purpose. It is a member of Metanoia's research family, but it works mainly by releasing the brain's own serotonin rather than mimicking it at this receptor, a different mechanism entirely. We show that honestly rather than force it into a tidier picture.
Shared 5-HT2A mechanism: Nichols DE, "Psychedelics," Pharmacol Rev 68(2):264-355, April 2016 · PMID 26841800 · DOI 10.1124/pr.115.011478. According to PubMed. Presented as education, not medical advice, and not a claim that any tradition's use was safe or legal in every setting.
Our ethical standards
All Metanoia research follows applicable laws and ethical guidelines. Advisory oversight is planned: our work will be reviewed by an advisory council now being formed. The approval processes in place today are an internal content council that reviews what we publish before it goes out, and a legal review gate. We will say here when more are in place. We're transparent about our methods and our limits, especially given the sensitive nature of this field. Metanoia conducts and shares research and education. We do not supply controlled substances.
We honor the traditional and Indigenous knowledge that these medicines come from, and we prioritize sustainable, cultivable sources over threatened or wild ones, respecting the source without appropriating it.